Astrazeneca (AZN) Short-term Investments (2016 - 2026)

Astrazeneca has reported Short-term Investments over the past 18 years, most recently at $382.0 million for Q1 2026.

For Q1 2026, Short-term Investments rose 81.9% year-over-year to $382.0 million; the TTM value through Mar 2026 reached $382.0 million, up 81.9%, while the annual FY2025 figure was $498.0 million, 1245.95% up from the prior year.
Short-term Investments for Q1 2026 was $382.0 million at Astrazeneca, down from $498.0 million in the prior quarter.
Over five years, Short-term Investments peaked at $509.0 million in Q2 2025 and troughed at -$290.0 million in Q3 2022.
A 5-year average of $169.9 million and a median of $163.0 million in 2023 define the central range for Short-term Investments.
Biggest five-year swings in Short-term Investments: plummeted 422.22% in 2022 and later soared 1245.95% in 2025.
Year by year, Short-term Investments stood at $87.0 million in 2022, then skyrocketed by 33.33% to $116.0 million in 2023, then tumbled by 68.1% to $37.0 million in 2024, then soared by 1245.95% to $498.0 million in 2025, then fell by 23.29% to $382.0 million in 2026.
Business Quant data shows Short-term Investments for AZN at $382.0 million in Q1 2026, $498.0 million in Q4 2025, and $502.0 million in Q3 2025.

Peer Comparison